Patent Application
20220090010
This application is submitted with a Sequence Listing text file in ASCII format, which serves as both the computer readable form (CFR) and the paper copy as required under 37 C.F.R. § 1.821. Said Sequence Listing text file is: entitled “37944_0013P1_ST25.txt”, 101,756 bytes in size, created on Jun. 19, 2021, and incorporated by reference in its entirety.
The present disclosure relates generally to methods of culturing pluripotent stem cells in defined conditions, inducing the pluripotent stem cells to differentiate into enteric neural crest cells, then the neural crest cells are cultured to produced spheroids, which in turn are induced to differentiate into enteric neurons. The resulting enteric neurons are suitable for screening potential therapeutic agents for the treatment of enteric neuropathies such as gastroparesis, esophageal achalasia, chronic intestinal pseudo-obstruction, and hypertrophic pyloric stenosis, and applications in regenerative medicine.
During embryogenesis, neural crest (NC) induction occurs at the interface of the non-neuronal ectoderm and the folding neural plate as a result of bone morphogenic protein (BMP), fibroblast growth factor (FGF), and Wnt signaling pathway activity (1). During neurulation, dorsally localized NC cells delaminate and migrate away from the newly formed neural tube. Migratory NC cells proliferate and act as progenitors for a remarkable diversity of cell types including various populations of peripheral neurons and glia, melanocytes, endocrine cells and mesenchymal precursor cells (1-3). In the developing embryo, the neural crest shows an anterior-posterior spatial organization associated with the expression of regionally specific HOX genes. Distinct functional regions include the cranial NC, vagal NC, trunk NC and sacral NC located anteriorly to posteriorly respectively (
While the enteric nervous system (ENS) is generated from both the vagal and sacral NC, vagal NC lineages positive for HOXB3 (4) and HOXB5 (5) migrate most extensively to colonize the entire length of the bowel (6) (arrows in
Post migratory ENC cells will commit to neuronal fates, a differentiation step associated with the downregulation of SOX10, sustained expression of EDNRB, ASCL1 and PHOX2B, and upregulation of pan neuronal markers such as TUJ1 (9). ENC progenitors further differentiate to establish ganglia located between the circular and longitudinal layers of enteric smooth muscle, forming the myenteric plexus. Recent spatiotemporal analysis of the murine ENS has shown that ENC progenitors within the myenteric plexus proliferate along the serosa-mucosal axis to subsequently form the ganglia of the submucosal plexus (10). Together, the myenteric and submucosal plexi will establish the neuronal circuitry of the functional ENS.
Due to the capacity of the NC to undergo an extensive range of cell fate decisions, protocols seeking to optimize NC induction and subtype specification from hPSCs have been an important focus of research (11-13). Such hPSC-based NC protocols commonly rely on a variation of the dual SMAD signaling inhibition protocol for neural induction, combined with the temporal activation of WNT signaling (12-14). However, such methods often involve the use of poorly defined culture components such as serum, BSA fractions, and other animal-derived products, that may affect the reliability and reproducibility of NC induction (e.g. Comparative Example 2). Accordingly, the inventors and others have reported protocols that use fully defined, xeno-free culture conditions for the reliable induction of cranial NC from hPSCs (15, 16).
The spatial and temporal transience of the ENC has been a major factor in limiting access to primary cells, particularly from human embryonic or fetal tissue samples. As a result, studying the developing ENS has largely relied upon studies in murine models. Work with such murine models resulted in the discovery of growth factors involved in the proliferation and differentiation of EN precursors, such as Neurotrophin-3 (NT-3) and glial cell line-derived neurotrophic factor (GDNF) (17, 18) among others. More recent single cell transcriptomics analysis of the developing murine ENS have revealed novel molecular states of lineally and functionally related ENS progenitors (10). An appreciable conservation of the transcriptional processes underpinning ENS development across mammals (19) supports the application of these factors to direct hPSC-derived ENC cells towards neurogenic commitments and may help further guide the identification, characterization and derivation of human enteric neuronal subtype lineages.
Therefore, there remains a need for novel protocols for derivation of enteric neurons (ENs) from hPSCs and a basis for modeling ENS development and the contribution of specific lineages to ENS disease.
The disclosure relates to a method of differentiating at least one or a plurality of stem cells into at least one or a plurality of enteric neurons, the method comprising (i) exposing the one or plurality of stem cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of stem cells into neural crest cells; and (ii) exposing the one or plurality of neural crest cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of neural crest cells into one or a plurality of enteric neurons. In some embodiments, the method further comprises performing step (ii) after the neural crest cells are plated into one or a plurality of spheroids. In some embodiments, the differentiation factor is an amino acid sequence of BMP4 or a functional fragment thereof. In some embodiments, the differentiation factor is retinoic acid or an analogue thereof. In some embodiments, the differentiation factor is SB431542 or an analogue thereof. In some embodiments, the differentiation factor is an amino acid sequence of FGF2 or a functional fragment thereof. In some embodiments, the differentiation factor is CHIR 99021 or an analogue thereof.
In some embodiments, the methods relate to i) exposing one or plurality of stem cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of stem cells into neural crest cells; and (ii) exposing the one or plurality of neural crest cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of neural crest cells into one or a plurality of enteric neurons; wherein in step (i) the one or plurality of stem cells are exposed to at least one or a combination of: BMP4 or a functional fragment thereof, SB431542 or an analogue thereof, and/or CHIR 99021 or an analogue thereof. In some embodiments, the methods relate to i) exposing one or plurality of stem cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of stem cells into neural crest cells; and (ii) exposing the one or plurality of neural crest cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of neural crest cells into one or a plurality of enteric neurons; wherein in step (ii) the one or plurality of neural crest cells are exposed to at least one or a combination of: FGF2 or a functional fragment thereof, SB431542 or an analogue thereof, and/or CHIR 99021 or an analogue thereof, and retinoic acid or an analogue thereof.
The disclosure also provides a fully defined differentiation protocol that integrates retinoic acid (RA), effectively transitioning the induction of cranial NC to a specific vagal NC regional identity (16). In one aspect, a method of culturing pluripotent stem cells comprises:
In one aspect the culture medium is removed and replaced with fresh culture medium about every 2 days. Suitable culture medium includes E8-C medium. In some embodiments, the culture medium comprises a Rho kinase inhibitor, e.g., Y-27632. In some embodiments, the culture medium comprising the Rho-kinase inhibitor is removed from the culture vessel 3-5 hours after plating, followed by addition of E8-C medium free of any Rho kinase inhibitor to the culture vessel.
In one aspect, the pluripotent stem cells are human pluripotent stem cells, e.g., human ES cell line H9 (WA-09), human ES cell line UCSF4, and human iPS cell line WTC11.
In one aspect, the hydrogel comprises MATRIGEL® or vitronectin.
In one aspect, the pluripotent stem cells are passaged at least twice. In some embodiments, passaging comprises:
In one embodiment, a method of producing an in vitro model of the enteric nervous system comprises:
In one embodiment, the pluripotent stem cells are human ES cell line UCSF4, and wherein an induction efficiency at day 11 is at least 25%, at least 30%, or at least 35% as measured by expression of CD49D. In one embodiment, the induction efficiency at day 15 is at least 70%, at least 80%, or at least 90%.
In one embodiment, the pluripotent stem cells are human iPS cell line WTC11, and wherein an induction efficiency at day 11 is at least 10%, at least 15%, or at least 20% as measured by expression of CD49D. In one embodiment, the induction efficiency at day 15 is at least 65%, is at least 75%, or at least 85%. In one embodiment, the induction efficiency at day 20 is at least 25%, at least 30%, or at least 35% as measured by expression of TUJ1 and TRKC. In one embodiment, the induction efficiency at day 40 is at least 40%, at least 50%, or at least 60%. In one embodiment, the induction efficiency at day 55 is at least 50%, at least 55% or at least 60%.
In one embodiment, inducing the pluripotent stem cells for the second time and under conditions sufficient to differentiate the induced pluripotent stem cells into enteric neural crest cells (ENCs) comprises:
Suitable defined medium includes E8-C medium. In one embodiment, the first induction medium is free of a SMAD signaling inhibitor. In one embodiment, the first induction medium comprises BMP4. In one embodiment, the first induction medium is Cocktail A, as described in Example 1. In one embodiment, the second induction medium is Cocktail B, as described in Example 1. In one embodiment, the third induction medium comprises retinoic acid. In one embodiment, the third induction medium is Cocktail C, as described in Example 1.
Exemplary enteric neural crest cells express at least one of HoxB2, HoxB5, and PAX3 at about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% higher than expressed by pluripotent stem cells.
In one embodiment, culturing the neural crest cells for the third time and under conditions for the neural crest cells to grow into enteric neural crest spheroids comprises incubating the neural crest cells in an ultra-low attachment culture vessel. In one embodiment, the third time is about 3 to about 4 days.
In one embodiment, the enteric neurons express at least one of CHAT, 5-HT, GABA, nNOS. In one embodiment, the CHAT induction efficiency is about 30% to about 50%. In one embodiment, the 5-HT induction efficiency is about 1% to about 15%. In one embodiment, the GABA induction efficiency is about 1% to about 20%. In one embodiment, the nNOS induction efficiency is about 1% to about 20%. In one embodiment, the enteric neurons comprise cholinergic and nitrergic neurons comprising co-expression of CHAT and NOS1 of at least about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% greater than enteric neural crest cells. In one embodiment, enteric neurons comprise glial cells that express GFAP and SOX10 at least 5% greater than enteric neural crest cells.
In one embodiment, a system comprises:
In one embodiment, the cells comprising expression of smooth muscle actin are flat myofibroblast like cells and/or mesenchymal precursors.
In some embodiments, the culture vessel comprises a multi-well plate. In some embodiments, the hydrogel comprises MATRIGEL®, vitronectin, GELTREX®, and/or CULTREX® BME.
The disclosure provides novel protocols for derivation of enteric neurons from hPSCs (
Further aspects of the disclosure include engrafting hPSC-derived ENC cells within host colons, e.g., murine host colon, and differentiate into functional ENs (16). Therefore, the inventors contemplate that EN cells of the disclosure find applications in regenerative medicine, e.g., to cure enteric neuropathies of the gastrointestinal tract via EN cell transplantation (21). The inventors contemplate use of the methods disclosed herein to derive ENs from hPSCs under highly defined conditions in the production clinical grade cells suitable for translational applications in the treatment of enteric neuropathies. The inventors further contemplate using the methods disclosed herein to produce pluripotent stem cell derived enteric neural cells of different cell type and state of differentiation. It should be appreciated that such cells may be used to replace damaged or absent cells relevant to enteric neuropathies. Moreover systems of the disclosure provide translational applications that present a rational approach for preclinical development and as research tools.
The protocol described herein provides improved methods for the derivation of enteric neural progenitors from pluripotent stem cells (22). Many labs in the stem cell field no longer rely on the support of feeder cells and have adopted the use of defined basal media, such as MTESR™ 1 (Stemcell Tech, 85850) or Essential 8 (Life Technologies, A2858501) for the maintenance of hPSC lines. Nevertheless, previous ENC induction methods commonly involve media containing serum replacement factors, namely knockout serum replacement (KSR), as is also the case in Comparative Example 2 (14, 20). In an effort to reduce the inconsistencies and quality control measures that undefined conditions may introduce to a protocol, we have pursued optimizing ENC induction in minimal, chemically defined conditions.
Recent studies have implemented alternative strategies for general NC induction using hPSCs, namely free floating embryoid body based approaches (23, 24). The migratory cells that come as a result of embryoid body and subsequent neural rosette formations have been shown to be positive for neural crest specific markers Sox10, TFAP2A, BRN3A, ISL1 and ASCL1, and a subset found to be positive for regionally specific vagal markers HOXB2 and HOXB5, even without the inclusion of RA (23). Overall neural crest induction efficiency was assessed by FACS of p75 and HNK1 double positive cells, a strategy used to isolate NC cells in previous protocols (Lee et al. 2007). Results showed >60% induction efficiency in ES cell line H9 and across independent hiPSC lines (23). Enriched NC populations were then co-cultured with primary gut explants in a Transwell system to promote ENC identities enriched for HOXB2, HOXB3, HAND2 and EDNRB. Notably, this method incorporates brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), neurotrophin-3 (NT3) into culture conditions. How these factors affect commitments of EN precursors, namely identities positive for VIP and calretinin (23), remains an interesting point of inquiry. A similar embryoid body approach incorporated brief exposure to RA during NC induction before eventually combining hPSC-derived NC cells with hPSC-derived intestinal organoids (HIOs) (24). In terms of the potential in ENC induction efficiency, comparative data between monolayer and embryoid body strategies remains limited. Indeed, the appropriate use of each strategy for a given application should be explored further.
The disclosure presents a protocol for the derivation of EN lineages from hPSCs. The development and utility of Comparative Example 2 was previously established in Fattahi et al., 2016 (16). The disclosure provides methods of deriving enteric neuron lineages following chemically defined and reliable methods.
The important points of difference between Examples 1 and 2 are found in maintenance of hPSCs (Step 1) and during the ENC induction phase (Step 2). Adoption of Essential 8 (E8) offers a chemically defined basal media for the maintenance of hPSCs (26), in place of the feeder cell and KSR media used in Comparative Example 2. Transition from E8 to E6 basal media, in conjunction with precise combinations of BMP and Wnt signaling, and addition of RA, trigger the developmental cues required for ENC induction. Comparative Example 2 requires the gradual titration between relative amounts of basal media KSR and N2, while exemplary methods of the disclosure utilizes a single defined basal media E6. Consequently, Comparative example 1 involves dual SMAD inhibition using SB431542 and LDN-193189, while the conditions of the methods described herein only demand the TGFβ signaling inhibition using SB431542. As a result of replacing the KSR used in Comparative Example 2, early activation of low levels of BMP signaling with BMP4 induces NC specification under the defined conditions described herein. For both options, CHIR 99021 is used to activate canonical Wnt signaling, though lower concentrations are used in the conditions of the present disclose, and for both methods, retinoic acid is used to pattern NC cells towards the vagal ENC identity. A schematic illustration is provided outlining the induction conditions of Comparative Example 2 (Supplementary
The disclosure relates to a method of differentiating at least one or a plurality of stem cells into at least one or a plurality of enteric neurons, the method comprising (i) exposing the one or plurality of stem cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of stem cells into neural crest cells; and (ii) exposing the one or plurality of neural crest cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of neural crest cells into one or a plurality of enteric neurons. In some embodiments, the method further comprises performing step (ii) after the neural crest cells are plated into one or a plurality of spheroids. In some embodiments, the differentiation factor is an amino acid sequence of BMP4 or a functional fragment thereof. In some embodiments, the differentiation factor is retinoic acid or an analogue thereof. In some embodiments, the differentiation factor is SB431542 or an analogue thereof. In some embodiments, the differentiation factor is an amino acid sequence of FGF2 or a functional fragment thereof. In some embodiments, the differentiation factor is CHIR 99021 or an analogue thereof.
In some embodiments, the methods relate to i) exposing one or plurality of stem cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of stem cells into neural crest cells; and (ii) exposing the one or plurality of neural crest cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of neural crest cells into one or a plurality of enteric neurons; wherein in step (i) the one or plurality of stem cells are exposed to at least one or a combination of: BMP4 or a functional fragment thereof, SB431542 or an analogue thereof, and/or CHIR 99021 or an analogue thereof. In some embodiments, the methods relate to i) exposing one or plurality of stem cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of stem cells into neural crest cells; and (ii) exposing the one or plurality of neural crest cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of neural crest cells into one or a plurality of enteric neurons; wherein in step (ii) the one or plurality of neural crest cells are exposed to at least one or a combination of: FGF2 or a functional fragment thereof, SB431542 or an analogue thereof, and/or CHIR 99021 or an analogue thereof, and retinoic acid or an analogue thereof. In some embodiments, the methods are free of steps of exposing any of the one or plurality of stem cells or neural crest cells to either of basal media KSR and N2 media.
In some embodiments the one or plurality of stem cells comprises an embryonic stem cell. In some embodiments, the one or plurality of stem cells comprises a pluripotent stem cell. In some embodiments the one or plurality of stem cells comprises a human embryonic stem cell. In some embodiments, the one or plurality of stem cells comprises a human pluripotent stem cell. In some embodiments, the one or plurality of stem cells comprises an induced human pluripotent stem cell. In some embodiments the one or plurality of stem cells comprises as hematopoetic stem cells, neural stem cells, adipose derived stem cells, bone marrow derived stem cells, induced pluripotent stem cells, astrocyte derived induced pluripotent stem cells, fibroblast derived induced pluripotent stem cells, renal epithelial derived induced pluripotent stem cells, keratinocyte derived induced pluripotent stem cells, peripheral blood derived induced pluripotent stem cells, hepatocyte derived induced pluripotent stem cells, mesenchymal derived induced pluripotent stem cells, neural stem cell derived induced pluripotent stem cells, adipose stem cell derived induced pluripotent stem cells, preadipocyte derived induced pluripotent stem cells, chondrocyte derived induced pluripotent stem cells, and skeletal muscle derived induced pluripotent stem cells.
Improved induction efficiency has been observed, when hPSCs are cultured under the maintenance conditions described in Examples 1 and 2 for several passages before differentiation. The density of hPSCs at the beginning of ENC induction also influences induction efficiency. In some embodiments the disclosure relates to a method of improving induction efficiency of stem cells into enteric neurons, the method comprising (i) exposing the one or plurality of stem cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of stem cells into neural crest cells; and (ii) exposing the one or plurality of neural crest cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of neural crest cells into one or a plurality of enteric neurons. In some embodiments, the method of improving induction efficiency of stem cells into enteric neurons comprises (i) exposing the one or plurality of stem cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of stem cells into neural crest cells; and (ii) exposing the one or plurality of neural crest cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of neural crest cells into one or a plurality of enteric neurons. In some embodiments, the method further comprises performing step (ii) after the neural crest cells are plated into one or a plurality of spheroids. In some embodiments, the differentiation factor is an amino acid sequence of BMP4 or a functional fragment thereof. In some embodiments, the differentiation factor is retinoic acid or an analogue thereof. In some embodiments, the differentiation factor is SB431542 or an analogue thereof. In some embodiments, the differentiation factor is an amino acid sequence of FGF2 or a functional fragment thereof. In some embodiments, the differentiation factor is CHIR 99021 or an analogue thereof. In some embodiments, the methods relate to i) exposing one or plurality of stem cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of stem cells into neural crest cells; and (ii) exposing the one or plurality of neural crest cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of neural crest cells into one or a plurality of enteric neurons; wherein in step (i) the one or plurality of stem cells are exposed to at least one or a combination of: BMP4 or a functional fragment thereof, SB431542 or an analogue thereof, and/or CHIR 99021 or an analogue thereof. In some embodiments, the methods relate to i) exposing one or plurality of stem cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of stem cells into neural crest cells; and (ii) exposing the one or plurality of neural crest cells to a disclosed differentiation factor or a functional fragment thereof for a time period and in an amount sufficient to differentiate the one or plurality of neural crest cells into one or a plurality of enteric neurons; wherein in step (ii) the one or plurality of neural crest cells are exposed to at least one or a combination of: SB431542 or an analogue thereof, and/or CHIR 99021 or an analogue thereof, and retinoic acid or an analogue thereof.
In any of the disclosed methods, some embodiments are free of exposing any of the one or plurality of stem cells or neuronal crest cells to a SAMD inhibitor.
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. For example, Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, N.Y. 1994), provide one skilled in the art with a general guide to many of the terms used in the present application. Additionally, the practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, 2nd edition (Sambrook et al., 1989); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); “Animal Cell Culture” (R. I. Freshney, ed., 1987); “Methods in Enzymology” (Academic Press, Inc.); “Handbook of Experimental Immunology”, 4th edition (D. M. Weir & C. C. Blackwell, eds., Blackwell Science Inc., 1987); “Gene Transfer Vectors for Mammalian Cells” (J. M. Miller & M. P. Calos, eds., 1987); “Current Protocols in Molecular Biology” (F. M. Ausubel et al., eds., 1987); and “PCR: The Polymerase Chain Reaction”, (Mullis et al., eds., 1994).
As used in the present disclosure and claims, the singular forms “a”, “an” and “the” include plural forms unless the context clearly dictates otherwise.
It is understood that wherever embodiments are described herein with the language “comprising” otherwise analogous embodiments described in terms of “consisting of” and/or “consisting essentially of” are also provided. It is also understood that wherever embodiments are described herein with the language “consisting essentially of” otherwise analogous embodiments described in terms of “consisting of” are also provided.
The term “and/or” as used in a phrase such as “A and/or B” herein is intended to include both A and B; A or B; A (alone); and B (alone). Likewise, the term “and/or” as used in a phrase such as “A, B, and/or C” is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
The term “about” or “approximately” as used herein is meant to refer to within 5%, or more preferably within 1%, of a given value or range.
The term “culture vessel” as used herein is defined as any vessel suitable for growing, culturing, cultivating, proliferating, propagating, or otherwise similarly manipulating cells. A culture vessel may also be referred to herein as a “culture insert”. In some embodiments, the culture vessel is made out of biocompatible plastic and/or glass. In some embodiments, the plastic is a thin layer of plastic comprising one or a plurality of pores that allow diffusion of protein, nucleic acid, nutrients (such as heavy metals and hormones) antibiotics, and other cell culture medium components through the pores. in some embodiments, the pores are not more than about 0.1, 0.5 1.0, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 microns wide. In some embodiments, the culture vessel in a hydrogel matrix and free of a base or any other structure. In some embodiments, the culture vessel is designed to contain a hydrogel or hydrogel matrix and various culture mediums. In some embodiments, the culture vessel consists of or consists essentially of a hydrogel or hydrogel matrix. In some embodiments, the only plastic component of the culture vessel is the components of the culture vessel that make up the side walls and/or bottom of the culture vessel that separate the volume of a well or zone of cellular growth from a point exterior to the culture vessel. In some embodiments, the culture vessel comprises a hydrogel and one or a plurality of isolated glial cells. In some embodiments, the culture vessel comprises a hydrogel and one or a plurality of isolated glial cells, to which one or a plurality of neuronal cells are seeded.
The term “exposing” as used herein refers to bringing a disclosed compound and a cell, target receptor, or other biological entity together in such a manner that the compound can affect the activity of the cell (e.g., receptor, cell, etc.), either directly; i.e., by interacting with the target or cell itself, or indirectly; i.e., by interacting with another molecule, co-factor, factor, or protein on which the activity of the cell is dependent. In some embodiments, the activity of cell is differentiation. In some embodiments, the compound is one or more differentiation factors.
“Analogues” of the compounds disclosed herein are pharmaceutically acceptable salts, prodrugs, deuterated forms, radio-actively labeled forms, isomers, solvates and combinations thereof. The “combinations” mentioned in this context are refer to derivatives falling within at least two of the groups: pharmaceutically acceptable salts, prodrugs, deuterated forms, radio-actively labeled forms, isomers, and solvates. Examples of radio-actively labeled forms include compounds labeled with tritium, phosphorous-32, iodine-129, carbon-11, fluorine-18, and the like. The compounds described herein may be present in the form of pharmaceutically acceptable salts. For use in medicines, the salts of the compounds described herein refer to non-toxic “pharmaceutically acceptable salts.” Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts. Suitable pharmaceutically acceptable acid addition salts of the compounds described herein include e.g., salts of inorganic acids (such as hydrochloric acid, hydrobromic, phosphoric, nitric, and sulfuric acids) and of organic acids (such as, acetic acid, benzenesulfonic, benzoic, methanesulfonic, and p-toluenesulfonic acids). Examples of pharmaceutically acceptable base addition salts include e.g., sodium, potassium, calcium, ammonium, organic amino, or magnesium salt. As used herein, the term “salt” refers to acid or base salts of the compounds used in the methods of the present disclosure. Illustrative examples of acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts.
The term “pluripotent stem cell” as used herein is defined as a cell that is self-replicating capable of developing into cells and tissues of the three primary germ layers. Pluripotent stem cells include embryonic and induced pluripotent cells as defined herein. Contemplated pluripotent stem cells originate from mammals, e.g., human, mouse, rat, monkey, horse, goat, sheep, dog, cat etc.
The term “induced pluripotent stem cell” (iPSC) means a type of pluripotent cell made by reprogramming a somatic cell to have the same properties as embryonic stem cells, namely, the ability to self-renew and differentiate into the three primary germ layers. In some embodiments, iPSCs include mammalian cells, e.g., human, mouse, rat, monkey, horse, goat, sheep, dog, cat etc., reprogrammed to express Oct4, Nanog, Sox2, and optionally c-Myc. In some embodiments, iPSCs comprise reprogrammed primary cell lines. In some embodiments iPSCs are obtained from a repository, such as the Coriell Institute for Medical Research (e.g., Catalog ID GM25256 (WTC-11), GM25430, GM23392, GM23396, GM24666, GM27177, GM24683), California Institute for Regenerative Medicine: California's Stem Cell Agency (e.g., CW60261, CW60354, CW60359, CW60480, CW60335, CW60280, CW60594, CW60083, CW60086, CW60087 CW60167, CW60186), and the American Type Culture Collection (ATCC®) (e.g., ATCC-DYR0530 Human Induced Pluripotent Stem (IPS) Cells (ATCC® ACS-1012™, ATCC® ACS-1011™, ATCC® Number: ACS-1024™, ATCC® Number: ACS-1028™, ATCC® Number: ACS-1031™, ATCC® Number: ACS-1004™, ATCC® Number: ACS-1029™, ATCC® Number: ACS-1020™, ATCC® Number: ACS-1007™, ATCC® Number: ACS-1030™) Induced pluripotent stem cells may be derived from cell types such as fibroblasts taken from the skin, lung, or vein of subjects that are apparently healthy or diseased.
As defined herein, the term “inhibition,” “inhibit,” “inhibiting,” and the like in reference to a protein-inhibitor (e.g., antagonist) interaction means negatively affecting (e.g., decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In embodiments inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a signal transduction pathway or signaling pathway. Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein.
The term “embryonic stem cell line” as used herein is defined as a cell derived from the inner cell mass of the pre-implantation blastocyst capable of self-renewal and differentiation into the three primary germ layers. In some embodiments, embryonic stem cell lines listed in the NIH Human Embryonic Stem Cell Registry, e.g., CHB-1, CHB-2, CHB-3, CHB-4, CHB-5, CHB-6, CHB-8, CHB-9, CHB-10, CHB-11, CHB-12, RUES1, RUES2, HUES 1, HUES 2, HUES 3, HUES 4, HUES 5, HUES 6, HUES 7, HUES 8, HUES 9, HUES 10, HUES 11, HUES 12, HUES 13, HUES 14, HUES 15, HUES 16, HUES 17, HUES 18, HUES 19, HUES 20, HUES 21, HUES 22, HUES 23, HUES 24, HUES 26, HUES 27, HUES 28, CyT49, RUES3, WA01 (H1), UCSF4, NYUES1, NYUES2, NYUES3, NYUES4, NYUES5, NYUES6, NYUES7, MFS5, HUES 48, HUES 49, HUES 53, HUES 65, HUES 66, UCLA 1, UCLA 2, UCLA 3, WA07 (H7), WA09 (H9), WA13 (H13), WA14 (H14), HUES 62, HUES 63, HUES 64, CT1, CT2, CT3, CT4, MA135, Endeavour-2, WIBR1, WIBR2, HUES 45, Shef 3, Shef 6, WIBR3, WIBR4, WIBR5, WIBR6, BJNhem19, BJNhem20, SA001, SA002, UCLA 4, UCLA 5, UCLA 6, HUES PGD 13, HUES PGD 3, ESI-014, ESI-017, HUES PGD 11, HUES PGD 12, WA15, WA16, WA17, WA18, WA19, etc. In some embodiments, embryonic stem cells comprise gene(s) associated with diseases or disorders.
The term “enteric neural crest cell” means a cell produced by inducing differentiation of a pluripotent stem cell, wherein the enteric neural crest cell expresses SOX10, PHOX2B, EDNRB, TFAP2A, BRN3A, ISL1 and/or ASCL1. In some embodiments, the neural crest cell is present in an embryoid body or neural rosette. In some embodiments, the neural crest cell expresses vagal markers HOXB2, HOXB3, and/or HOXB5. In some embodiments, neural crest cells express p75 and HNK1. In some embodiments, neural crest cells express HOXB2, HOXB3, HAND2 and EDNRB.
The term “enteric neuron” means a cell produced by inducing differentiation of an enteric neural crest cell, wherein the enteric neuron exhibits downregulation of SOX10, sustained expression of EDNRB, ASCL1 and PHOX2B, and upregulation of TUJ1 and TRKC. In some embodiments enteric neurons express neuronal subtype specific markers including the cholinergic neuronal marker Choline Acetyl Transferase (CHAT), serotonin (5-HT) receptor, gamma-Aminobutyric acid (GABA), and neuronal nitric oxide synthase (nNOS). In some embodiments, CHAT expression indicates the presence of cholinergic neurons. In some embodiments, expression of NOS1 indicates the presence of nitrergic neurons. In some embodiments, enteric neurons include glial cells expressing glial fibrillary acidic protein (GFAP) and SOX10.
The term “rho kinase inhibitor” means a compound that decreases the activity of rho kinase. In some embodiments, the rho kinase inhibitor is N-[(3-Hydroxyphenyl)methyl]-N′-[4-(4-pyridinyl)-2-thiazolyl]urea dihydrochloride (RKI-1447), (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride (Y-27632), Fasudil (HA-1077), Hydroxyfasudil (HA 1100 hydrochloride), Thiazovivin, GSK429286A, Narciclasine, and/or (+)-(R)-trans4-(1-aminoethyl)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)cyclohexanecarboxamide dihydrochloride (Y-30141).
The term “hydrogel” as used herein is defined as any water-insoluble, crosslinked, three-dimensional network of polymer chains with the voids between polymer chains filled with or capable of being filled with water. The term “hydrogel matrix” as used herein is defined as any three-dimensional hydrogel construct, system, device, or similar structure. In some embodiments, the hydrogel or hydrogel matrix comprises one or more proteins and/or glycoproteins. In some embodiments, the hydrogel or hydrogel matrix comprises one or more of the following proteins: collagen, gelatin, elastin, titin, laminin, fibronectin, fibrin, keratin, silk fibroin, and any derivatives or combinations thereof. In some embodiments, the hydrogel or hydrogel matrix comprises MATRIGEL® or vitronectin. In some embodiments, the hydrogel or hydrogel matrix can be solidified into various shapes, for example, a bifurcating shape designed to mimic a neuronal tract. In some embodiments, the hydrogel or hydrogel matrix comprises poly (ethylene glycol) dimethacrylate (PEG). In some embodiments, the hydrogel or hydrogel matrix comprises Puramatrix. In some embodiments, the hydrogel or hydrogel matrix comprises glycidyl methacrylate-dextran (MeDex). In some embodiments, two or more hydrogels or hydrogel matrixes are used simultaneously cell culture vessel. In some embodiments, two or more hydrogels or hydrogel matrixes are used simultaneously in the same cell culture vessel but the hydrogels are separated by a wall that create independently addressable microenvironments in the tissue culture vessel such as wells. In a multiplexed tissue culture vessel it is possible for some embodiments to include any number of aforementioned wells or independently addressable location within the cell culture vessel such that a hydrogel matrix in one well or location is different or the same as the hydrogel matrix in another well or location of the cell culture vessel.
The term “MATRIGEL®” means a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma comprising ECM proteins including laminin, collagen IV, heparin sulfate proteoglycans, entactin/nidogen, and other growth factors. In some embodiments, CULTREX® BME (Trevigen, Inc.) or GELTREX® (Thermo-Fisher Inc.) may be substituted for MATRIGEL®.
The term “vitronectin” means a protein encoded by the VTN gene. In some embodiments, vitronectin has at least 70% sequence identity with SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or a fragment thereof.
The term “biomarker” as used herein refers to a biological molecule present in an individual at varying concentrations useful in predicting the cancer status of an individual. A biomarker may include but is not limited to, nucleic acids, proteins and variants and fragments thereof. A biomarker may be DNA comprising the entire or partial nucleic acid sequence encoding the biomarker, or the complement of such a sequence. Biomarker nucleic acids useful in the invention are considered to include both DNA and RNA comprising the entire or partial sequence of any of the nucleic acid sequences of interest.
Choline Acetyl Transferase (CHAT) refers to an enzyme that catalyzes the transfer of an acetyl group from the coenzyme acetyl-CoA to choline, yielding acetylcholine (ACh). In some embodiments, CHAT has at least 70% sequence identity with SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or a fragment thereof.
sapiens OX = 9606 GN = CHAT PE = 1 SV = 4
norvegicus OX = 10116 GN = Chat PE = 1 SV = 2
musculus OX = 10090 GN = Chat PE = 2 SV = 2
“Serotonin receptors” or “5-hydroxytryptamine (5-HT) receptors” are G protein-coupled receptor and ligand-gated ion channels found in the central and peripheral nervous systems. Serotonin activates the serotonin receptors, mediating both excitatory and inhibitory neurotransmission. In some embodiments, serotonin receptors have at least 70% sequence identity with SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or a fragment thereof.
sapiens OX = 9606 GN = HTR1A PE = 1 SV = 3
norvegicus OX = 10116 GN = Htr1a PE = 1 SV = 1
musculus OX = 10090 GN = Htr1a PE = 2 SV = 2
Gamma-Aminobutyric acid (GABA) acts as a trophic factor to modulate several essential developmental processes including neuronal proliferation, migration, and differentiation.
Neuronal nitric oxide synthase (nNOS) produces nitric oxide (NO) in the central and peripheral nervous systems. In some embodiments, nNOS has at least 70% sequence identity with SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, or a fragment thereof.
sapiens OX = 9606 GN = NOS1 PE = 1 SV = 2
norvegicus OX = 10116 GN = Nos1 PE = 1 SV = 1
musculus OX = 10090 GN = Nos1 PE = 1 SV = 1
Glial fibrillary acidic protein (GFAP) is a class-III intermediate filament. During the development of the central nervous system, GFAP is a cell-specific marker that distinguishes astrocytes from other glial cells. In some embodiments, GFAP has at least 70% sequence identity with SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or a fragment thereof.
sapiens OX = 9606 GN = GFAP PE = 1 SV = 1
norvegicus OX = 10116 GN = Gfap PE = 1 SV = 2
musculus OX = 10090 GN = Gfap PE = 1 SV = 4
Enteric neural crest cells express SOX10, which directs the activity of other genes that signal neural crest cells to become more specific cell types including enteric nerves. In some embodiments, SOX10 has at least 70% sequence identity with SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, or a fragment thereof.
sapiens OX = 9606 GN = SOX10 PE = 1 SV = 1
norvegicus OX = 10116 GN = Sox10 PE = 1 SV = 1
musculus OX = 10090 GN = Sox10 PE = 1 SV = 2
The term “two-dimensional culture” as used herein is defined as cultures of cells on flat hydrogels, including MATRIGEL® and vitronectin, disposed in culture vessels.
As used herein, a “spheroid” or “cell spheroid” means any grouping of cells in a three-dimensional shape that generally corresponds to an oval or circle rotated about one of its principal axes, major or minor, and includes three-dimensional egg shapes, oblate and prolate spheroids, spheres, and substantially equivalent shapes.
A spheroid of the present invention can have any suitable width, length, thickness, and/or diameter. In some embodiments, a spheroid may have a width, length, thickness, and/or diameter in a range from about 10 μm to about 50,000 μm, or any range therein, such as, but not limited to, from about 10 μm to about 900 μm, about 100 μm to about 700 μm, about 300 μm to about 600 m, about 400 μm to about 500 μm, about 500 μm to about 1,000 μm, about 600 μm to about 1,000 μm, about 700 μm to about 1,000 μm, about 800 μm to about 1,000 am, about 900 μm to about 1,000 μm, about 750 μm to about 1,500 μm, about 1,000 μm to about 5,000 μm, about 1,000 μm to about 10,000 μm, about 2,000 to about 50,000 μm, about 25,000 μm to about 40,000 μm, or about 3,000 μm to about 15,000 m. In some embodiments, a spheroid may have a width, length, thickness, and/or diameter of about 50 μm, 100 μm, 200 μm, 300 μm, 400 μm, 500 am, 600 μm, 700 μm, 800 μm, 900 μm, 1,000 μm, 5,000 μm, 10,000 μm, 20,000 μm, 30,000 μm, 40,000 μm, or 50,000 m. In some embodiments, a plurality of spheroids are generated, and each of the spheroids of the plurality may have a width, length, thickness, and/or diameter that varies by less than about 20%, such as, for example, less than about 15%, 10%, or 5%. In some embodiments, each of the spheroids of the plurality may have a different width, length, thickness, and/or diameter within any of the ranges set forth above.
The cells in a spheroid may have a particular orientation. In some embodiments, the spheroid may comprise an interior core and an exterior surface. In some embodiments, the spheroid may be hollow (i.e., may not comprise cells in the interior). In some embodiments, the interior core cells and the exterior surface cells are different types of cell.
In some embodiments, spheroids may be made up of one, two, three or more different cell types, including one or a plurality of neuronal cell types and/or one or a plurality of stem cell types. In some embodiments, the interior core cells may be made up of one, two, three, or more different cell types. In some embodiments, the exterior surface cells may be made up of one, two, three, or more different cell types.
In some embodiments, the spheroids comprise at least two types of cells. In some embodiments the spheroids comprise neuronal cells and non-neuronal cells. In some embodiments, the spheroids comprise neuronal cells and astrocytes at a ratio of about 5:1, 4:1, 3:1, 2:1 or 1:1 of neuronal cells to astrocytes. In some embodiments, the spheroids comprise neuronal cells and non-neuronal cells at a ratio of about 5:1, 4:1, 3:1, 2:1 or 1:1. In some embodiments, the spheroids comprise neuronal cells and non-neuronal cells at a ratio of about 1:5: 1:4, 1:3, or 1:2. Any combination of cell types disclosed herein may be used in the above-identified ratios within the spheroids of the disclosure.
Depending on the particular embodiment, groups of cells may be placed according to any suitable shape, geometry, and/or pattern. For example, independent groups of cells may be deposited as spheroids, and the spheroids may be arranged within a three dimensional grid, or any other suitable three dimensional pattern. The independent spheroids may all comprise approximately the same number of cells and be approximately the same size, or alternatively, different spheroids may have different numbers of cells and different sizes. In some embodiments, multiple spheroids may be arranged in shapes such as an L or T shape, radially from a single point or multiple points, sequential spheroids in a single line or parallel lines, tubes, cylinders, toroids, hierarchically branched vessel networks, high aspect ratio objects, thin closed shells, organoids, or other complex shapes which may correspond to geometries of tissues, vessels or other biological structures.
The term “subject” as used herein refers to any animal (e.g., a mammal), including, but not limited to, humans, non-human primates, canines, felines, rodents, and the like. Preferably, the subject is a human subject. The terms “subject,” “individual,” and “patient” are used interchangeably herein. The terms “subject,” “individual,” and “patient” thus encompass individuals having cancer (e.g., breast cancer), including those who have undergone or are candidates for resection (surgery) to remove cancerous tissue.
A “therapeutically effective amount” of a therapeutic agent, or combinations thereof, is an amount sufficient to treat disease in a subject.
The terms “treating” or “treatment” or “treat” as used herein refer to therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder.
The term “preventing” or “prevention” or “prevent” as used herein refers to prophylactic or preventative measures that prevent or slow the development of a targeted pathologic condition or disorder. Those in need of treatment include those already diagnosed with the disorder; those prone to have the disorder; and those in whom the disorder is to be prevented.
Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, also specifically contemplated and considered disclosed is the range from the one particular value and/or to the other particular value unless the context specifically indicates otherwise. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another, specifically contemplated embodiment that should be considered disclosed unless the context specifically indicates otherwise. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint unless the context specifically indicates otherwise. The term “about” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
The “percent identity” or “percent homology” of two polynucleotide or two polypeptide sequences is determined by comparing the sequences using the GAP computer program (a part of the GCG Wisconsin Package, version 10.3 (Accelrys, San Diego, Calif.)) using its default parameters. “Identical” or “identity” as used herein in the context of two or more nucleic acids or amino acid sequences, may mean that the sequences have a specified percentage of residues that are the same over a specified region. The percentage may be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity. In cases where the two sequences are of different lengths or the alignment produces one or more staggered ends and the specified region of comparison includes only a single sequence, the residues of single sequence are included in the denominator but not the numerator of the calculation. When comparing DNA and RNA, thymine (T) and uracil (U) may be considered equivalent. Identity may be performed manually or by using a computer sequence algorithm such as BLAST or BLAST 2.0. Briefly, the BLAST algorithm, which stands for Basic Local Alignment Search Tool is suitable for determining sequence similarity. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length Win the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension for the word hits in each direction are halted when: 1) the cumulative alignment score falls off by the quantity X from its maximum achieved value; 2) the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or 3) the end of either sequence is reached. The Blast algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The Blast program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff et al., Proc. Natl. Acad. Sci. USA, 1992, 89, 10915-10919, which is incorporated herein by reference in its entirety) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands. The BLAST algorithm (Karlin et al., Proc. Natl. Acad. Sci. USA, 1993, 90, 5873-5787, which is incorporated herein by reference in its entirety) and Gapped BLAST perform a statistical analysis of the similarity between two sequences. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide sequences would occur by chance. For example, a nucleic acid is considered similar to another if the smallest sum probability in comparison of the test nucleic acid to the other nucleic acid is less than about 1, less than about 0.1, less than about 0.01, and less than about 0.001. Two single-stranded polynucleotides are “the complement” of each other if their sequences can be aligned in an anti-parallel orientation such that every nucleotide in one polynucleotide is opposite its complementary nucleotide in the other polynucleotide, without the introduction of gaps, and without unpaired nucleotides at the 5′ or the 3′ end of either sequence. A polynucleotide is “complementary” to another polynucleotide if the two polynucleotides can hybridize to one another under moderately stringent conditions. Thus, a polynucleotide can be complementary to another polynucleotide without being its complement.
The terms “functional fragment” means any portion of a polypeptide or nucleic acid sequence from which the respective full-length polypeptide or nucleic acid relates that is of a sufficient length and has a sufficient structure to confer a biological affect that is at least similar or substantially similar to the full-length polypeptide or nucleic acid upon which the fragment is based. In some embodiments, a functional fragment is a portion of a full-length or wild-type nucleic acid sequence that encodes any one of the nucleic acid sequences disclosed herein, and said portion encodes a polypeptide of a certain length and/or structure that is less than full-length but encodes a domain that still biologically functional as compared to the full-length or wild-type protein. In some embodiments, the functional fragment may have a reduced biological activity, about equivalent biological activity, or an enhanced biological activity as compared to the wild-type or full-length polypeptide sequence upon which the fragment is based. In some embodiments, the functional fragment is derived from the sequence of an organism, such as a human. In such embodiments, the functional fragment may retain 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity to the wild-type human sequence upon which the sequence is derived. In some embodiments, the functional fragment may retain 85%, 80%, 75%, 70%, 65%, or 60% sequence identity to the wild-type sequence upon which the sequence is derived.
By “fragment” is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least about about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or about 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more nucleotides or amino acids.
“Variants” is intended to mean substantially similar sequences. For nucleic acid molecules, a variant comprises a nucleic acid molecule having deletions (i.e., truncations) at the 5′ and/or 3′ end; deletion and/or addition of one or more nucleotides at one or more internal sites in the native polynucleotide; and/or substitution of one or more nucleotides at one or more sites in the native polynucleotide. As used herein, a “native” nucleic acid molecule or polypeptide comprises a naturally occurring nucleotide sequence or amino acid sequence, respectively. For nucleic acid molecules, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the polypeptides of the disclosure. Variant nucleic acid molecules also include synthetically derived nucleic acid molecules, such as those generated, for example, by using site-directed mutagenesis but which still encode a protein of the disclosure. Generally, variants of a particular nucleic acid molecule of the disclosure will have at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to that particular polynucleotide as determined by sequence alignment programs and parameters as described elsewhere herein. Variants of a particular nucleic acid molecule of the disclosure (i.e., the reference DNA sequence) can also be evaluated by comparison of the percent sequence identity between the polypeptide encoded by a variant nucleic acid molecule and the polypeptide encoded by the reference nucleic acid molecule. Percent sequence identity between any two polypeptides can be calculated using sequence alignment programs and parameters described elsewhere herein. Where any given pair of nucleic acid molecule of the disclosure is evaluated by comparison of the percent sequence identity shared by the two polypeptides that they encode, the percent sequence identity between the two encoded polypeptides is at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity. In some embodiments, the term “variant” protein is intended to mean a protein derived from the native protein by deletion (so-called truncation) of one or more amino acids at the N-terminal and/or C-terminal end of the native protein; deletion and/or addition of one or more amino acids at one or more internal sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Variant proteins encompassed by the present disclosure are biologically active, that is they continue to possess the desired biological activity of the native protein as described herein. Such variants may result from, for example, genetic polymorphism or from human manipulation. Biologically active variants of a protein of the disclosure will have at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the amino acid sequence for the native protein as determined by sequence alignment programs and parameters described elsewhere herein. A biologically active variant of a protein of the disclosure may differ from that protein by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue. The proteins or polypeptides of the disclosure may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants and fragments of the proteins can be prepared by mutations in the nucleic acid sequence that encode the amino acid sequence recombinantly.
“Optional” or “optionally” means that the subsequently described event, circumstance, or material may or may not occur or be present, and that the description includes instances where the event, circumstance, or material occurs or is present and instances where it does not occur or is not present.
The term “culture vessel” as used herein is defined as any vessel suitable for growing, culturing, cultivating, proliferating, propagating, or otherwise similarly manipulating cells. A culture vessel may also be referred to herein as a “culture insert”. In some embodiments, the culture vessel is made out of biocompatible plastic and/or glass. In some embodiments, the plastic is a thin layer of plastic comprising one or a plurality of pores that allow diffusion of protein, nucleic acid, nutrients (such as heavy metals and hormones) antibiotics, and other cell culture medium components through the pores. In some embodiments, the pores are not more than about 0.1, 0.5 1.0, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 microns wide. In some embodiments, the culture vessel in a hydrogel matrix and free of a base or any other structure. In some embodiments, the culture vessel is designed to contain a hydrogel or hydrogel matrix and various culture mediums. In some embodiments, the culture vessel consists of or consists essentially of a hydrogel or hydrogel matrix. In some embodiments, the only plastic component of the culture vessel is the components of the culture vessel that make up the side walls and/or bottom of the culture vessel that separate the volume of a well or zone of cellular growth from a point exterior to the culture vessel. In some embodiments, the culture vessel comprises a hydrogel and one or a plurality of isolated stem cells and/or neural crest cells. In some embodiments, the culture vessel comprises enteric neurons. In some embodiments, the culture vessel comprises enteric neurons differentiated in culture form about 12 to about 20 days. In some embodiments, the culture vessel comprises a hydrogel and one or a plurality of isolated pluripotent stem cells.
In some embodiments, the hydrogel or hydrogel matrixes can have various thicknesses. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 150 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 200 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 250 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 300 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 350 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 400 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 450 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 500 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 550 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 600 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 650 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 700 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 750 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 750 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 700 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 650 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 600 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 550 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 500 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 450 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 400 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 350 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 300 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 250 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 200 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 150 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 300 μm to about 600 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 400 μm to about 500 μm.
In some embodiments, the hydrogel or hydrogel matrixes can have various thicknesses. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 10 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 150 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 200 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 250 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 300 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 350 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 400 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 450 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 500 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 550 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 600 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 650 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 700 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 750 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 800 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 850 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 900 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 950 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 1000 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 1500 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 2000 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 2500 μm to about 3000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 2500 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 2000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 1500 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 1000 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 950 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 900 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 850 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 800 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 750 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 700 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 650 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 600 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 550 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 500 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 450 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 400 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 350 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 300 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 250 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 200 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 100 μm to about 150 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 300 μm to about 600 μm. In some embodiments, the thickness of the hydrogel or hydrogel matrix is from about 400 μm to about 500 μm.
In some embodiments, the hydrogel or hydrogel matrix comprises one or more synthetic polymers. In some embodiments, the hydrogel or hydrogel matrix comprises one or more of the following synthetic polymers: polyethylene glycol (polyethylene oxide), polyvinyl alcohol, poly-2-hydroxyethyl methacrylate, polyacrylamide, silicones, and any derivatives or combinations thereof.
In some embodiments, the hydrogel or hydrogel matrix comprises one or more synthetic and/or natural polysaccharides. In some embodiments, the hydrogel or hydrogel matrix comprises one or more of the following polysaccharides: hyaluronic acid, heparin sulfate, heparin, dextran, agarose, chitosan, alginate, and any derivatives or combinations thereof.
In some embodiments, the hydrogel or hydrogel matrix comprises one or more proteins and/or glycoproteins. In some embodiments, the hydrogel or hydrogel matrix comprises one or more of the following proteins: collagen, gelatin, elastin, titin, laminin, fibronectin, fibrin, keratin, silk fibroin, and any derivatives or combinations thereof.
In some embodiments, the one or plurality of cells is stimulated by a differentiation factor. Differentiation factors may include one or a combination of any of the following:
In any of the methods or systems disclosed herein, the differentiation factors used may be functional fragments or variants of the polypeptides disclosed above with at least about 70% sequence identity to the above sequences. In any of the methods or systems disclosed herein, the differentiation factors used may be functional fragments or variants of the polypeptides disclosed above with at least about 80% sequence identity to the above sequences. In any of the methods or systems disclosed herein, the differentiation factors used may be functional fragments or variants of the polypeptides disclosed above with at least about 85% sequence identity to the above sequences. In any of the methods or systems disclosed herein, the differentiation factors used may be functional fragments or variants of the polypeptides disclosed above with at least about 90% sequence identity to the above sequences. In any of the methods or systems disclosed herein, the differentiation factors used may be functional fragments or variants of the polypeptides disclosed above with at least about 95% sequence identity to the above sequences. In any of the methods or systems disclosed herein, the differentiation factors used may be functional analogues of the small molecules disclosed above. The methods of the disclosure relate to the sequential exposure of a culture of cells to two or more different tissue culture mediums. In some embodiments, the methods relate to the sequential exposure of cells of the present disclosure to Cocktail Me
The present disclosure also relates to a system comprising: (i) a cell culture vessel optionally comprising a hydrogel; (ii) one or a plurality of stem cells or neural crest cells either in suspension or as a component of a spheroid; and (iii) on or plurality of differentiation factors. In some embodiments, the system further comprises one or combination of culture mediums disclosed herein. The disclosure also relates to a method of culturing enteric neurons in a system, the system comprising: (i) a cell culture vessel optionally comprising a hydrogel; (ii) one or a plurality of stem cells or neural crest cells either in suspension or as a component of a spheroid; and (iii) on or plurality of differentiation factors. In some embodiments, the system further comprises one or combination of culture mediums disclosed herein. In some embodiments, the methods relate to replacing medium during a culture time of form about 12 to about 21 days at least one time to (i) expose one or a plurality of stem cells to a first cell medium for a time period sufficient to differentiate the one or plurality of stem cells into neural crest cells and the sequentially replacing the medium to (ii) expose one or plurality of neural crest cells to a second cell medium for a time period sufficient to differentiate the one or plurality of neural crest cells into enteric neurons.
In some embodiments, the system comprises a solid substrate. The term “solid substrate” as used herein refers to any substance that is a solid support that is free of or substantially free of cellular toxins. In some embodiments, the solid substrate comprise one or a combination of silica, plastic, and metal. In some embodiments, the solid substrate comprises pores of a size and shape sufficient to allow diffusion or non-active transport of proteins, nutrients, and gas through the solid substrate in the presence of a cell culture medium. In some embodiments, the pore size is no more than about 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 micron microns in diameter. One of ordinary skill could determine how big of a pore size is necessary based upon the contents of the cell culture medium and exposure of cells growing on the solid substrate in a particular microenvironment. For instance, one of ordinary skill in the art can observe whether any cultured cells in the system or device are viable under conditions with a solid substrate comprises pores of various diameters. In some embodiments, the solid substrate comprises a base with a predetermined shape that defines the shape of the exterior and interior surface. In some embodiments, the base comprises one or a combination of silica, plastic, ceramic, or metal and wherein the base is in a shape of a cylinder or in a shape substantially similar to a cylinder, such that the first cell-impenetrable polymer and a first cell-penetrable polymer coat the interior surface of the base and define a cylindrical or substantially cylindrical interior chamber; and wherein the opening is positioned at one end of the cylinder. In some embodiments, the base comprises one or a plurality of pores of a size and shape sufficient to allow diffusion of protein, nutrients, and oxygen through the solid substrate in the presence of the cell culture medium. In some embodiments, the solid substrate comprises a plastic base with a pore size of no more than 1 micron in diameter and comprises at least one layer of hydrogel matrix wherein the solid substrate comprises at least one compartment defined at least in part by the shape of an interior surface of the solid substrate and accessible from a point outside of the solid substrate by an opening, optionally positioned at one end of the solid substrate. In embodiments, where the solid substrate comprises a hollow interior portion defined by at least one interior surface, the cells in suspension or tissue explants may be seeded by placement of cells at or proximate to the opening such that the cells may adhere to at least a portion the interior surface of the solid substrate for prior to growth. The at least one compartment or hollow interior of the solid substrate allows a containment of the cells in a particular three-dimensional shape defined by the shape of the interior surface. In some embodiments, the solid substrate and encourages directional growth of the cells away from the opening. In the case of neuronal cells, the degree of containment and shape of the at least one compartment are conducive to axon growth from soma positioned within the at least one compartment and at or proximate to the opening.
The present disclosure provides devices, methods, and systems involving production, maintenance, and physiological interrogation of neural cells in microengineered configurations designed to mimic native nerve tissue anatomy. It is another object of the disclosure to provide a medium to high-throughput assay of neurological function for the screening of pharmacological and/or toxicological properties of chemical and biological agents. In some embodiments, the agents are cells, such as any type of cell disclosed herein, or antibodies, such as antibodies that are used to treat clinical disease. In some embodiments, the agents are any drugs or agents that are used to treat human disease such that toxicities, effects or neuromodulation can be compared among a new agent which is a proposed mammalian treatment and existing treatments from human disease. In some embodiments, new agents for treatment of human disease are treatments for neurodegenerative disease and are compared to existing treatments for neurodegenerative disease.
Similarly, information gathered from imaging can determine quantitative metrics for the degree of cell toxicology and lends further insight into toxic and neuroprotective mechanisms of various agents or compounds of interest. In some embodiments, the at least one agent comprises a small chemical compound. In some embodiments, the at least one agent comprises at least one environmental or industrial pollutant. In some embodiments, the at least one agent comprises one or a combination of small chemical compounds chosen from: chemotherapeutics, analgesics, cardiovascular modulators, cholesterol, neuroprotectants, neuromodulators, immunomodulators, anti-inflammatories, and anti-microbial drugs.
In some embodiments, the at least one agent comprises one or a combination of chemotherapeutics chosen from: Actinomycin, Alitretinoin, All-trans retinoic acid, Azacitidine, Azathioprine, Bexarotene, Bleomycin, Bortezomib, Capecitabine, Carboplatin, Chlorambucil, Cisplatin, Cyclophosphamide, Cytarabine, Dacarbazine (DTIC), Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Erlotinib, Etoposide, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Irinotecan, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitoxantrone, Nitrosoureas, Oxaliplatin, Paclitaxel, Pemetrexed, Romidepsin, Tafluposide, Temozolomide (Oral dacarbazine), Teniposide, Tioguanine (formerly Thioguanine), Topotecan, Tretinoin, Valrubicin, Vemurafenib, Vinblastine, Vincristine, Vindesine, Vinorelbine, Vismodegib, and Vorinostat. In some embodiments, the at least one agent comprises one or a combination of analgesics chosen from: Paracetoamol, Non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, opioids, flupirtine, tricyclic antidepressants, carbamaxepine, gabapentin, and pregabalin.
In some embodiments, the at least one agent comprises one or a combination of cardiovascular modulators chosen from: nepicastat, cholesterol, niacin, scutellaria, prenylamine, dehydroepiandrosterone, monatepil, esketamine, niguldipine, asenapine, atomoxetine, flunarizine, milnacipran, mexiletine, amphetamine, sodium thiopental, flavonoid, bretylium, oxazepam, and honokiol.
In some embodiments, the at least one agent comprises one or a combination of neuroprotectants and/or neuromodulators chosen from: tryptamine, galanin receptor 2, phenylalanine, phenethylamine, N-methylphenethylamine, adenosine, kyptorphin, substance P, 3-methoxytyramine, catecholamine, dopamine, GABA, calcium, acetylcholine, epinephrine, norepinephrine, and serotonin. In some embodiments, the at least one agent comprises one or a combination of immunomodulators chosen from: clenolizimab, enoticumab, ligelizumab, simtuzumab, vatelizumab, parsatuzumab, Imgatuzumab, tregalizaumb, pateclizumab, namulumab, perakizumab, faralimomab, patritumab, atinumab, ublituximab, futuximab, and duligotumab.
In some embodiments, the at least one agent comprises one or a combination of anti-inflammatories chosen from: ibuprofen, aspirin, ketoprofen, sulindac, naproxen, etodolac, fenoprofen, diclofenac, flurbiprofen, ketorolac, piroxicam, indomethacin, mefenamic acid, meloxicam, nabumetone, oxaprozin, ketoprofen, famotidine, meclofenamate, tolmetin, and salsalate. In some embodiments, the at least one agent comprises one or a combination of anti-microbials chosen from: antibacterials, antifungals, antivirals, antiparasitics, heat, radiation, and ozone.
Examples 1 and 2 were carried out with methods including, but not limited to, the following:
Materials—Reagents and Equipment
E8-C, hPSC Medium for Maintenance
Combine Essential 8-Flex supplement (20 μl ml−1) with ESSENTIAL 8™ Flex Medium. Store at 4° C. (use within 2 weeks).
Cocktail A, First ENC Differentiation Medium
Combine BMP4 (1 ng ml−1), SB431542 (10 μM), CHIR 99021 (600 nM), with ESSENTIAL 6™ Medium. Store at 4° C. (use within 2 weeks).
Cocktail B, Second ENC Differentiation Medium
Combine SB431542 (10 μM), CHIR 99021 (1.5 μM), with ESSENTIAL 6™ medium. Store at 4° C. (use within 2 weeks).
Cocktail C, Third ENC Differentiation Medium
Combine SB431542 (10 μM), CHIR 99021 (1.5 μM), Retinoic Acid (1 μM), with ESSENTIAL 6™ medium. Store at 4° C. (use within 2 weeks).
NC-C, ENC Medium for Spheroid Maintenance
Combine FGF2 (10 ng ml−1), CHIR 99021 (3 μM), N2 Supplement (10 μl ml−1), B27 Supplement (20 μl ml−1), Glutagro (10 μl ml−1), MEM Nonessential Amino Acids (10 μl ml−1), with NEUROBASAL® Medium. Store at 4° C. (use within 2 weeks).
EN-C, EN Medium for Differentiation and Maintenance
Combine GDNF (10 ng ml−1), Ascorbic Acid (100 μM), N2 Supplement (10 μl ml−1), B27 Supplement (20 μl ml−1), Glutagro (10 μl ml−1), MEM Nonessential Amino Acids (10 μl ml−1), with NEUROBASAL® Medium. Store at 4° C. (use within 2 weeks).
EDTA 1× for Passaging hESCs
Combine EDTA (500 μM) with PBS.
MATRIGEL®
Thaw frozen vial of MATRIGEL® overnight at 4° C. Prepare 500 μl aliquots in pre-chilled 50 ml conical tubes using chilled pipette tips and keep frozen at −20° C.
MATRIGEL®-Coated Plates Dilute a 500 μl frozen aliquot of MATRIGEL® in 50 ml of cold DMEM:F12. Pipette up and down vigorously with a 25 ml or 50 ml serological pipette to break frozen Matrigel® pellet. Coat wells with the diluted MATRIGEL® solution (100 μl/cm2 well surface area) and let stand in a 37° C. incubator overnight. Aspirate the MATRIGEL® solution before plating hPSCs.
Vitronectin-Coated Plates
Dilute vitronectin (10 μl ml−1) with PBS and mix thoroughly. Coat wells with diluted vitronectin solution (100 μl/cm2 well surface area) and let plates stand in a 37° C. incubator overnight. Aspirate the vitronectin solution before plating hPSCs. It should be appreciated that MATRIGEL®-coated plates yield a fully defined system, whereas vitronectin-coated plates yield a partially defined system.
PO/Lam/FN-Coated Plates
Combine PO (15 μg ml−1) with PBS. Coat wells with PO/PBS solution (100 μl/cm2 well surface area) and let stand in 37° C. incubator overnight. The following day, combine FN (2 μg ml−1) and Laminin (2 μg ml−1) with PBS. Aspirate PO/PBS and coat well with FN/LM/PBS solution (100 μl/cm2 well surface area). Let plates stand in 37° C. incubator for a minimum of 2 hours. Aspirate FN/LM/PBS solution before plating cells.
Methods
Thawing Frozen hPSCs
Store frozen stocks of hPSCs in a liquid nitrogen cryogenic storage system at −156° C. For hPSCs lines that were previously maintained in mTESR1, first establish the line in mTESR1 for the initial passage, before transitioning the cultures to E8 medium. The cultures should be passaged at least twice in new medium before continuing the protocol.
Step 1—Maintaining HPSC Cultures
Step 2-ENC Induction (Days 0-12)
Day −2: Replating hPSCs for Differentiation
Day 0: ENC Induction Begins
Day 2
Day 4
Day 6
Day 8
Day 10
Day 11/12
Step 3-ENC Spheroid (Day 12-15)
ENC monolayers are detached from the well surface and transferred to ultra-low attachment plates to form free floating 3D spheroids. Spheroids are maintained in NC-C medium for 3-4 days as part of a NC maintenance process (
Step 4-EN Induction Phase (Day 15-)
After the ENC spheroid phase (Step 3) and 15 total days from the start of ENC differentiation, ENC spheroids are dissociated with Accutase treatment and replated on PO/LM/FN-coated wells. This step marks the final replating of the protocol and the beginning of EN induction (
Results
The disclosed methods and systems reliably produce populations of hPSC-derived ENs under chemically defined conditions. Proportions of cells positive for EN identities may vary between cell lines, as well as between differentiations of a given cell line. Regardless, cells possessing a neuronal morphology should emerge by 20 days after the start of hPSC differentiation (Supplementary
The identification of CD49D (α4 integrin) as a reliable surface marker of SOX10+NC lineages (16), enables the assessment of the ENC induction efficiency and their prospective isolation. Analysis of CD49D expression after 12 and 15 days of differentiation under the disclosed method for two additional hPSC lines (hESC-UCSF4 and hiPSC-WTC11) (
Comparisons of relative gene expression between samples collected from separate time-points during differentiation reveal population level transitions in gene expression that are supported by previous descriptions of the transcriptional processes of in vivo ENS development (29). High expression levels of ENC-derived progenitor markers PHOX2B, ASCL1, and EDNRB during the transition to EN induction reveal the presence of enteric precursors (
NC-derived flat myofibroblast-like cells identifiable by expression of smooth muscle actin (SMA) have also been observed (Supplementary
Materials—Reagents and Equipment
ES Medium, hPSC Medium for Maintenance
Combine 100 ml of KSR to 400 ml DMEM/F12, no glutamine. Add 5 ml of 200 mM L-glutamine, and 5 ml of MEM Nonessential Amino Acids. Filter sterilize, then add 10 ng/ml of recombinant FGF2. Store at 4° C. (use within 2 weeks).
MEF Medium, MEF Culture Medium
Combine 100 ml FBS to 900 ml of DMEM. Filter sterilize before use. Store at 4° C. (use within 3 weeks).
KSR Medium, Early ENC Differentiation Medium
Combine 410 ml of Knockout DMEM, 75 ml of KSR, 5 ml of 200 mM L-glutamine), 5 ml of MEM non-essential amino acids, and 500 μl of 2-mercaptoethanol. Store at 4° C. (use within 3 weeks).
N2 Medium, Late ENC Differentiation Medium
Dissolve one bag of DMEM/F12 powder in 550 ml of distilled water. Add: 1.55 g of glucose, 2.00 g of sodium bicarbonate, 16.1 μg putrescine, 32 μg progesterone, 5.2 μg sodium selenite, 100 mg transferrin, 25 mg insulin (dissolved in 10 ml of 5 mM NaOH). Add double-distilled water (with a resistance of 18.2 M) to a final volume of 1000 ml. Filter sterilize and store at 4° C. in Option A (use within 3 weeks).
MEF-Coated Dishes
Prepare MEF coated 10-cm dish at least one day before hPSC passaging by coating culture surface with 0.1% gelatin dissolved in PBS (5 ml). Incubate at room temperature for 10 minutes. Thaw vial of mitomycin-C treated MEFs in a 37° C. water bath and resuspend cells in MEF medium (100,000 cells ml−1). Aspirate 0.1% gelatin and add ˜1.2×106 MEFs to 10-cm dish (15,000 cells/cm2 well surface area). Culture MEFs overnight in a 37° C. incubator. MEF coated dishes may be left cultured for up to 3 days before plating hPSCs.
Methods
Thawing Frozen hPSCs
Store frozen stocks of hPSCs in a liquid nitrogen cryogenic storage system at −156° C. For hPSCs lines that were previously maintained in mTESR1, first establish the line in mTESR1 for the initial passage, before transitioning the cultures to KSR based hES medium. The cultures should be passaged at least twice in new medium before continuing the protocol.
Plating hPSCs is performed as described in Example 1, substituting hESC-medium for E8-C medium and 6-well MEF-coated plates for MATRIGEL®-coated or vitronectin-coated plates.
Step 1—Maintaining HPSC Cultures
Step 2-ENC Induction (Days 0-12)
Day −1: Replating hPSCs for differentiation
Day 0: Neural Crest Induction Begins
Day 2
Day 4
Day 6
Day 8
Day 10
Day 11/12
Step 3-ENC Spheroid (Day 12-15)
ENC monolayers are detached from the well surface and transferred to ultra-low attachment plates to form free floating 3D spheroids as described in Example 1. Spheroids are maintained in NC-C medium for 3-4 days as part of a NC maintenance process.
Step 4-EN Induction Phase (Day 15→)
After the ENC spheroid phase (Step 3) and 15 total days from the start of ENC differentiation, ENC spheroids are dissociated with Accutase treatment and replated on PO/LM/FN-coated wells as described in Example 1.
Fluorescence Activated Cell Sorting (FACS)
After 12 days of ENC induction under (Step 3), fluorescence activated cell sorting (FACS) can be used to prepare purified populations of NC cells. Previous NC induction protocols have suggested using p75/HNK1 marker staining for FACS analysis11,13. However, p75 expression is found outside of the ENC and a portion of p75/HNK1 double positive cells have been shown to be SOX10::GFP− (12). We have demonstrated that CD49D (α4 integrin) is a specific marker for SOX10+ hPSC-derived NC lineages16. Here we present a procedure for the purification of ENC cells by FACS using CD49D. FACS purification is particularly recommended for experiments and assays that involve early ENC progenitors (day 11). Further differentiation under the 3D sphere culture condition is generally sufficient to enhance the purity of NC cells and neurons in the later stages of differentiation without FACS purification (
Reagents
Equipment
Reagent Setup
Staining Medium
Sorting Medium
Procedure
The application is a National Stage application filed under 35 U.S.C. § 371 of International Application No. PCT/US2019/068447, filed on Dec. 23, 2019, which claims priority to U.S. Provisional Application No. 62/783,795, filed on Dec. 21, 2018, which are incorporated by reference in their entireties.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2019/068447 | 12/23/2019 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62783795 | Dec 2018 | US |
